2022
Considerations in the management of hereditary angioedema due to C1-INH deficiency in women of childbearing age
Hsu FI, Lumry W, Riedl M, Tachdjian R. Considerations in the management of hereditary angioedema due to C1-INH deficiency in women of childbearing age. Allergy, Asthma & Clinical Immunology 2022, 18: 64. PMID: 35831891, PMCID: PMC9281160, DOI: 10.1186/s13223-022-00689-9.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsHereditary angioedemaHealth statusAdverse fetal outcomesCohort of patientsChoice of therapyContinuity of careMedical Advisory BoardC1-INH deficiencyWomen's health statusRisk-benefit assessmentHAE attacksHAE managementFetal outcomesProphylactic therapyPatient populationTreatment optionsFemale sexDisease burdenTreatment decisionsContraceptive useUnpredictable episodesTreatment efficacyMucous membranesGynecologic specialistsPregnancy
2020
Experience with Intravenous Plasma-Derived C1-Inhibitor in Pregnant Women with Hereditary Angioedema: A Systematic Literature Review
Brooks JP, Radojicic C, Riedl MA, Newcomer SD, Banerji A, Hsu FI. Experience with Intravenous Plasma-Derived C1-Inhibitor in Pregnant Women with Hereditary Angioedema: A Systematic Literature Review. The Journal Of Allergy And Clinical Immunology In Practice 2020, 8: 1875-1880.e3. PMID: 32251736, DOI: 10.1016/j.jaip.2020.03.009.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPlasma-derived C1-INHHereditary angioedemaC1-INHPregnant womenPlasma-derived C1 inhibitorC1 inhibitorTreatment guideline recommendationsFirst-line treatmentFavorable safety profileNumber of dosesEnglish-language articlesIntravenous plasmaGuideline recommendationsThird trimesterConsensus guidelinesSafety profileSpontaneous abortionPregnancySystematic reviewLanguage articlesAngioedemaLiterature searchData extractionTrimesterWomen